MaxCyte News
News
0
Ticker
MXCT
ISIN
US57777K1060
MaxCyte Eulerpool News
MaxCyte Stock News
MaxCyte is being monitored by journalists and investors worldwide. We gather the latest MaxCyte news here.
- December 1·Yahoo
- November 13·Yahoo
- November 7·Yahoo
- November 5·Yahoo
- November 5·Benzinga
- October 8·Yahoo
- October 6·Yahoo
- September 22·Benzinga
- August 11·Yahoo
- August 7·SeekingAlpha
- August 6·Benzinga
- August 4·Yahoo
- July 31·Yahoo
- July 22·Benzinga
- July 9·Yahoo
- July 1·Yahoo
- June 11·Yahoo
- June 11·Benzinga
- May 13·Yahoo
- May 8·Yahoo
MaxCyte Stock Press Releases
MaxCyte regularly publishes news on the company's website that are relevant for investors.
- November 9•MaxCyte
- November 2•MaxCyte
- October 12•MaxCyte
- September 28•MaxCyte
- September 21•MaxCyte
- September 7•MaxCyte
- August 10•MaxCyte
- July 15•MaxCyte
- July 12•MaxCyte
- May 13•MaxCyte
- May 9•MaxCyte
- May 3•MaxCyte
- April 20•MaxCyte
- April 15•MaxCyte
- April 12•MaxCyte
- March 22•MaxCyte
- March 9•MaxCyte
- February 24•MaxCyte
- February 14•MaxCyte
- February 11•MaxCyte
- February 1•MaxCyte
- January 24•MaxCyte
- November 12•MaxCyte
- November 10•MaxCyte
- November 3•MaxCyte
- October 29•MaxCyte
- October 28•MaxCyte
- October 25•MaxCyte
- September 17•MaxCyte
- September 13•MaxCyte
MaxCyte News 2026
This page contains all current news, analysis and press releases for MaxCyte stock (MXCT, ISIN: US57777K1060). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at MaxCyte.
MaxCyte Stock
MaxCyte MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products.